Media Coverage header image

Media Coverage

Advanced Search
  • 05092019
    360Dx

    Oxford Immunotec reported today a 27 percent year-over-year increase in first quarter revenues primarily on growth in tuberculosis testing in all geographies.

    For the three months ended March 31, 2019, Oxford Immunotec logged $14.8 million in total revenues compared to $11.7 million in the year-ago period. On a constant-currency basis, Q1 revenues increased 39 percent year over year.

    On a conference call following release of the company's earnings, Oxford Immunotec CEO Peter Wrighton-Smith noted that revenues came in above the company's implied guidance range of $13.4 million to $14.1 million.

  • 05082019
    Yahoo Finance

    Investors with a long-term horizong may find it valuable to assess Quest Diagnostics Incorporated's (NYSE:DGX) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. Below is my commentary, albiet very simple and high-level, on how Quest Diagnostics is currently performing.

  • 05072019
    JD Supra

    Before diving into an analysis of these and similar questions, it’s important to get on the same page regarding the substance. Cannabidiol – or CBD – is a chemical found in marijuana and its close relative, hemp. Pure CBD does not contain tetrahydrocannabinol (THC), the psychoactive ingredient found in marijuana that produces a high.[CR-LF][CR-LF]The most common CBD formulation started as oil, but CBD is also sold as an extract, a vaporized liquid, and an oil-based capsule. CBD-infused beverages are probably the most common CBD product, but use of CBD-based cosmetic and skincare products is surging in both retail stores and online.[CR-LF][CR-LF]This means that one of your workers or applicants might think they are staying on the right side of the law when using a CBD product, but could inadvertently ingest substances that violate your valid drug policies. Barry Sample, the Director of Science and Technology for the drug testing laboratory Quest Diagnostics, recently observed that the government is not ensuring the level of THC remains low because CBD oil is not regulated in the United States. Therefore, he said, “if somebody is using a CBD oil that contains residual THC in it, they very likely could test positive on a urine drug test. Not because of the CBD itself – but because of a contaminant that is in that oil.”

  • 05032019
    The-Fly

    Shares of LabCorp moved lower following the afternoon disclosure and are trading down $1.51 to $164.12. LabCorp competitor Quest Diagnostics (DGX) gave up some of its gains as well but the shares remain up 51c to $98.67 in afternoon trading.

  • 05022019
    360Dx

    While the ultimate impact of UnitedHealthcare's newly launched Preferred Laboratory Network remains to be seen, some clinical lab players are suggesting it could be the first step in a broader trend.[CR-LF][CR-LF]Last week UHC announced the lab companies — AmeriPath/DermPath, a division of Quest Diagnostics; BioReference and its GeneDx business; Invitae; Laboratory Corporation of America; Mayo Clinical Laboratories; and Quest — it had selected as participants in its PLN program, which will go into effect on July 1, 2019.

  • 05022019
    The-Fly

    Healthcare Technology Analyst Gill holds a conference call with CEO Rusckowski on May 2 at 1 pm hosted by JPMorgan.

  • 05022019
    Global Legal Chronicle

    Quest Diagnostics Incorporated executed a shelf takedown of $500 million aggregate principal amount of its 4.200% senior notes due 2029. Goldman Sachs, Mizuho Securities, Morgan Stanley, J.P. Morgan Securities and Wells Fargo Securities acted as joint book-running managers for the offering.[CR-LF][CR-LF]Quest Diagnostics Incorporated is the world’s leading provider of diagnostic information services.

  • 05022019
    American Industrial Hygiene Association

    The most recent version of an annual report issued by Quest Diagnostics indicates that 4.4 percent of workplace drug tests in 2018 were positive for illicit drugs, an increase over the 4.2 percent positivity rate in 2017 and the highest rate since 2004. According to Quest, the increase was largely fueled by marijuana use. Across the U.S. work force, the percentage of drug tests that were positive for marijuana rose from 2.6 percent in 2017 to 2.8 percent in 2018.

  • 05022019
    One News Page

    Genomic Vision (Paris:GV) (FR0011799907 - GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced its revenue and cash position1 at March 31, 2019. First quarter 2019 revenue In € thousands Q1 2019 Q1 2018 Revenue from R&D collaboration with Quest Diagnostics 75 75 Sales of products and

  • 05012019
    360Dx

    With the recent formation of the Get the Medications Right (GTMRx) Institute, Quest Diagnostics and the other institute co-founders aim to drive the use of advanced diagnostics for guiding patient treatment.[CR-LF][CR-LF]Launched this month by organizations including J&J, Medecision, and the American College of Clinical Pharmacy, the institute will function "as an advocacy entity" for companion diagnostics and pharmacogenomic testing, said Steve Goldberg, vice president, medical affairs, population health and chief health officer, health and wellness at Quest, and a member of the GTMRx board.

  • 04302019
    LossPrevention Online

    Changes in state laws regarding the treatment of marijuana, which are in direct conflict with federal law, have raised concerns and caused confusion among employers and employees regarding standards for drug-free workplaces and employment drug testing procedures and programs. An Arizona US District Judge is the latest to weigh in on the matter—ruling on the side of a Walmart worker who had been fired after failing a company drug test.[CR-LF][CR-LF]US employers are feeling the impact of liberalized marijuana laws, according to employment drug testing performed by Quest Diagnostics, a leading provider of diagnostic information services.

  • 04302019
    St. Cloud Times Online

    One day after the Texas House overwhelmingly voted to virtually decriminalize the possession of small amounts of marijuana for first-time offenders, the president of the Texas Senate effectively drove a stake through the heart of the measure.[CR-LF][CR-LF]"I join with those House Republicans who oppose this step toward legalization of marijuana," Lt. Gov. Dan Patrick said in a tweet Tuesday morning. Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

  • 04302019
    Modern Healthcare

    An alliance of independent health systems across Massachusetts has expanded from three to 10 organizations, enabling them to leverage cheaper contracts while maintaining their autonomy.[CR-LF][CR-LF]The Massachusetts Value Alliance, which initially formed in 2016, is a collaboration of 14 hospitals in the state that work together on group purchasing contracts and share best practices in order to be competitive in their market while still remaining independent. The combined health systems serve about 2 million people. Since the Massachusetts alliance formed three years ago, the organizations have worked together to negotiate on lab referral contracts. The members waited until their contracts were up and decided to go forward with one contract with Quest Diagnostics.

  • 04292019
    SHRM Online

    More U.S. workers are testing positive for marijuana while the number testing positive for opioids continues to decline, according to the annual Quest Diagnostics Drug Testing Index.[CR-LF][CR-LF]Based on an analysis of nine million drug tests conducted in 2018, Quest determined that 5.1 percent of the general workforce tested positive for drugs and another 2.7 percent of workers in safety-sensitive positions regulated by federal law did so. Those in safety-sensitive jobs include pilots; rail, bus and truck drivers; and workers in nuclear power plants.

  • 04292019
    Healthcare Finance News Online

    As hospitals turn to technology to overhaul the patient experience and improve profits, a range of vendors from are bring new products and outsourced services to meet that demand with artificial intelligence, data analytics and natural language processing as well as cognitive and process automation.The end-to-end solution may not work for every system, but all providers are looking to modernize. Some do it through Optum products such as computer assisted coding technologies with natural language processing baked in.[CR-LF][CR-LF]Using partner Quest Diagnostics, Optum360 can predict patient responsibility at the point of service.

  • 04282019
    USA Today Online

    As attorneys argued over a section of an Arizona law that differentiates between marijuana and cannabis, the state’s Supreme Court justices joked about baking pot brownies in their kitchens.[CR-LF][CR-LF]They clearly do not understand how the marijuana industry has irresponsibly manipulated pot into dangerously high levels of potency.[CR-LF]Marijuana use is on the rise among US workers, a study from Quest Diagnostics found, increasing by 16% since 2014.

  • 04272019
    Baseball Daily News

    Major testing lab Quest Diagnostics says a small proportion of workforce tests nationally come back positive for marijuana or any other drugs, but the number has been growing in recent years.[CR-LF][CR-LF]Including job applicants and hired workers, the positive-test rate for marijuana was 2.8% last year, up from 2.4% in 2014, the Secaucus, New Jersey-based company said Thursday.

  • 04262019
    360Dx

    UnitedHealthcare this week named seven labs to its new Preferred Laboratory Network. They are AmeriPath/DermPath, a division of Quest Diagnostics; BioReference and its GeneDx lab; Invitae; Laboratory Corporation of America; Mayo Clinic Laboratories; and Quest. PLN's goal is threefold: to make healthcare affordable, improve outcomes, and improve the patient experience, UHC said in a statement. PLN launches on July 1, 2019. While UHC customers can choose a lab not in PLN, the price of services accessed through the network will be lower, UHC said, noting that pathology services for a biopsy in PLN would be $90 compared to $150 outside of PLN.

  • 04262019
    KTVK-TV Online

    The number of people caught cheating on employer-required drug tests rose by 40% from 2017 to 2018, according to figures compiled by Quest Diagnostics.[CR-LF][CR-LF]"This is common," said Tim Terrill, the owner of ARCPoint Labs of Scottsdale - North.

  • 04262019
    KTVK-TV Online

    The number of people caught cheating on employer-required drug tests rose by 40% from 2017 to 2018, according to figures compiled by Quest Diagnostics.

  • 04242019
    Early Start - CNN

    Hasbro, Twitter and Quest Diagnostics were among the best performers of the day. last year, they had the worst trading day ever. s&p 500 is up 17% this year

  • 04232019
    Medical Health News

    A simple test using a swab of cells from the inside of your cheek can dramatically improve your medical treatment. The test can predict whether a drug will help, if you need a different dosage, or if you are at risk of severe side effects.[CR-LF][CR-LF]This testing is called pharmacogenetics or pharmacogenomics. This means studying the interactions of drugs (pharma-) and an individual’s genes (genom-). Genes control how drugs are metabolized and may be different in different people. Treatment can be personalized, or individualized for some classes of drugs.[CR-LF][CR-LF]Several companies provide different panels for pharmacogenetic testing. Some are mostly focused on psychiatric drugs, like Myriad Genetics’ (MYGN: Nasdaq) pricey GeneSight test, at $2000. There are the big labs, like LabCorp (NYSE: LH), Quest Diagnostics (NYSE: DGX), Mayo Clinics, and smaller companies which focus only on pharmacogenomics, like Genelex, a private company. In choosing a lab, look at certification, the types of panels of testing that are offered (and whether they include the enzymes metabolizing the drugs you are taking), and the type of explanation they provide you and your physician.

  • 04232019
    Schaeffers Research

    New home sales, the Richmond Fed manufacturing survey, and the FHFA home price index data will surface. JetBlue (JBLU), Quest Diagnostics (DGX), Sherwin-Williams (SHW), Snap (SNAP), TD Ameritrade (AMTD), and Texas Instruments (TXN) are on the earnings schedule.

  • 04232019
    PR News Online

    Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2019.[CR-LF][CR-LF]"We're off to a good start in 2019, with solid volume growth from our expanded health plan access," said Steve Rusckowski, Chairman, President and CEO. "As we anticipated, volume accelerated through the quarter, and we look forward to continued progress as a member of UnitedHealthcare's Preferred Lab Network beginning July 1. We continue to drive productivity to address ongoing reimbursement pressure, and are well positioned to meet our financial commitments for the remainder of 2019."

  • 04232019
    360Dx

    Quest Diagnostics today reported revenues for its first quarter were up a fraction of 1 percent year over year.[CR-LF][CR-LF]For the three months ended March 31, total revenues inched up to $1.89 billion from $1.88 billion in Q1 2018, beating analysts' average estimate of $1.87 billion. Revenues from Diagnostic Information Services grew to $1.81 billion from $1.80 billion.[CR-LF][CR-LF]On a conference call following the release of the results, Quest President, CEO, and Chairman Steve Rusckowsi said that test volume grew almost 4 percent year over year. Key test growth drivers in the quarter included tuberculosis, Cardio IQ, drug monitoring, and hemapathology blood cancer testing, "all of which showed revenue growth" in Q1.

Show 5102550100 per page